UZH-Logo

Maintenance Infos

KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy


Mortezavi, A; Hermanns, T; Seifert, H H; Baumgartner, M; Provenzano, M; Sulser, T; Burger, M; Montani, M; Ikenberg, K; Hofstaedter, F; Hartmann, A; Jaggi, R; Moch, H; Kristiansen, G; Wild, P J (2011). KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clinical Cancer Research, 17(5):1111-1121.

Abstract

PURPOSE: To analyze rates of expression of karyopherin alpha 2 (KPNA2) in different prostate tissues and to evaluate the prognostic properties for patients with primary prostate cancer. EXPERIMENTAL DESIGN: Tissue microarrays containing 798 formalin-fixed, paraffin-embedded prostate tissue cores from two different institutes of pathology. TMAs were stained immunhistochemically for KPNA2 and NBS1. SiRNA technologies were used to inhibit KPNA2 expression in vitro, and the effect of this inhibition on cellular viability was determined. Efficency of knock down experiments was determined by Western blot analysis.RESULTS: KPNA2 expression was significantly upregulated in carcinomas of the prostate, especially in metastatic and castration-resistant prostate cancer samples. Positive nuclear KPNA2 immunoreactivity was identified as a novel predictor of biochemical recurrence after radical prostatectomy (n=348), and was independent of the well-established predictive factors preoperative PSA value, Gleason score, tumor stage and surgical margin status. These results were validated by analyzing a second and independent prostate cancer cohort (n=330). Further, in vitro experiments showed that the cell proliferation and viability of PC3 cells was significantly reduced when KPNA2 expression was inhibited. KPNA2 knockdown did not induce poly(ADP-ribose) polymerase (PARP) cleavage as marker for apoptosis. No significantly increased subG1 fraction could be found by FACS analysis. CONCLUSIONS: KPNA2 is a novel independent prognostic marker for disease progression after radical prostatectomy. This allows to identify patients who need more aggressive treatment. It can moreover be speculated that patients not suited for surveillance regimens might be identified at initial biopsy by a positive KPNA2 immunohistochemistry.

PURPOSE: To analyze rates of expression of karyopherin alpha 2 (KPNA2) in different prostate tissues and to evaluate the prognostic properties for patients with primary prostate cancer. EXPERIMENTAL DESIGN: Tissue microarrays containing 798 formalin-fixed, paraffin-embedded prostate tissue cores from two different institutes of pathology. TMAs were stained immunhistochemically for KPNA2 and NBS1. SiRNA technologies were used to inhibit KPNA2 expression in vitro, and the effect of this inhibition on cellular viability was determined. Efficency of knock down experiments was determined by Western blot analysis.RESULTS: KPNA2 expression was significantly upregulated in carcinomas of the prostate, especially in metastatic and castration-resistant prostate cancer samples. Positive nuclear KPNA2 immunoreactivity was identified as a novel predictor of biochemical recurrence after radical prostatectomy (n=348), and was independent of the well-established predictive factors preoperative PSA value, Gleason score, tumor stage and surgical margin status. These results were validated by analyzing a second and independent prostate cancer cohort (n=330). Further, in vitro experiments showed that the cell proliferation and viability of PC3 cells was significantly reduced when KPNA2 expression was inhibited. KPNA2 knockdown did not induce poly(ADP-ribose) polymerase (PARP) cleavage as marker for apoptosis. No significantly increased subG1 fraction could be found by FACS analysis. CONCLUSIONS: KPNA2 is a novel independent prognostic marker for disease progression after radical prostatectomy. This allows to identify patients who need more aggressive treatment. It can moreover be speculated that patients not suited for surveillance regimens might be identified at initial biopsy by a positive KPNA2 immunohistochemistry.

Citations

45 citations in Web of Science®
49 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

244 downloads since deposited on 12 Mar 2011
62 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology
04 Faculty of Medicine > University Hospital Zurich > Urological Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2011
Deposited On:12 Mar 2011 17:17
Last Modified:05 Apr 2016 14:42
Publisher:American Association for Cancer Research
ISSN:1078-0432
Additional Information:content over 12 months old is free to all
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:10.1158/1078-0432.CCR-10-0081
PubMed ID:21220479
Permanent URL: http://doi.org/10.5167/uzh-44422

Download

[img]
Preview
Content: Accepted Version
Filetype: PDF
Size: 884kB
View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations